EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update

R. Agca, S. C. Heslinga, S. Rollefstad, M. Heslinga, I. B. McInnes, M. J L Peters, T. K. Kvien, M. Dougados, H. Radner, F. Atzeni, J. Primdahl, A. Södergren, S. Wallberg Jonsson, J. van Rompay, C. Zabalan, T. R. Pedersen, L. Jacobsson, K. de Vlam, M. A. Gonzalez-Gay, A. G. SembG. D. Kitas, Y. M. Smulders, Z. Szekanecz, N. Sattar, D. P M Symmons, M. T. Nurmohamed

Research output: Contribution to journalArticle

284 Citations (Scopus)

Abstract

Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal antiinflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.

Original languageEnglish
JournalAnnals of the Rheumatic Diseases
DOIs
Publication statusAccepted/In press - Oct 3 2016

Fingerprint

Risk Management
Disease Management
Risk management
Rheumatic Diseases
Rheumatoid Arthritis
Cardiovascular Diseases
Joints
Expert Testimony
Patient Advocacy
Psoriatic Arthritis
Ankylosing Spondylitis
Politics
Adrenal Cortex Hormones
Screening
Anti-Inflammatory Agents
Health
Guidelines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders : 2015/2016 update. / Agca, R.; Heslinga, S. C.; Rollefstad, S.; Heslinga, M.; McInnes, I. B.; Peters, M. J L; Kvien, T. K.; Dougados, M.; Radner, H.; Atzeni, F.; Primdahl, J.; Södergren, A.; Jonsson, S. Wallberg; van Rompay, J.; Zabalan, C.; Pedersen, T. R.; Jacobsson, L.; de Vlam, K.; Gonzalez-Gay, M. A.; Semb, A. G.; Kitas, G. D.; Smulders, Y. M.; Szekanecz, Z.; Sattar, N.; Symmons, D. P M; Nurmohamed, M. T.

In: Annals of the Rheumatic Diseases, 03.10.2016.

Research output: Contribution to journalArticle

Agca, R, Heslinga, SC, Rollefstad, S, Heslinga, M, McInnes, IB, Peters, MJL, Kvien, TK, Dougados, M, Radner, H, Atzeni, F, Primdahl, J, Södergren, A, Jonsson, SW, van Rompay, J, Zabalan, C, Pedersen, TR, Jacobsson, L, de Vlam, K, Gonzalez-Gay, MA, Semb, AG, Kitas, GD, Smulders, YM, Szekanecz, Z, Sattar, N, Symmons, DPM & Nurmohamed, MT 2016, 'EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update', Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2016-209775
Agca, R. ; Heslinga, S. C. ; Rollefstad, S. ; Heslinga, M. ; McInnes, I. B. ; Peters, M. J L ; Kvien, T. K. ; Dougados, M. ; Radner, H. ; Atzeni, F. ; Primdahl, J. ; Södergren, A. ; Jonsson, S. Wallberg ; van Rompay, J. ; Zabalan, C. ; Pedersen, T. R. ; Jacobsson, L. ; de Vlam, K. ; Gonzalez-Gay, M. A. ; Semb, A. G. ; Kitas, G. D. ; Smulders, Y. M. ; Szekanecz, Z. ; Sattar, N. ; Symmons, D. P M ; Nurmohamed, M. T. / EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders : 2015/2016 update. In: Annals of the Rheumatic Diseases. 2016.
@article{0934f140d54045a79dfdc5c0e91871c9,
title = "EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update",
abstract = "Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal antiinflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.",
author = "R. Agca and Heslinga, {S. C.} and S. Rollefstad and M. Heslinga and McInnes, {I. B.} and Peters, {M. J L} and Kvien, {T. K.} and M. Dougados and H. Radner and F. Atzeni and J. Primdahl and A. S{\"o}dergren and Jonsson, {S. Wallberg} and {van Rompay}, J. and C. Zabalan and Pedersen, {T. R.} and L. Jacobsson and {de Vlam}, K. and Gonzalez-Gay, {M. A.} and Semb, {A. G.} and Kitas, {G. D.} and Smulders, {Y. M.} and Z. Szekanecz and N. Sattar and Symmons, {D. P M} and Nurmohamed, {M. T.}",
year = "2016",
month = "10",
day = "3",
doi = "10.1136/annrheumdis-2016-209775",
language = "English",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders

T2 - 2015/2016 update

AU - Agca, R.

AU - Heslinga, S. C.

AU - Rollefstad, S.

AU - Heslinga, M.

AU - McInnes, I. B.

AU - Peters, M. J L

AU - Kvien, T. K.

AU - Dougados, M.

AU - Radner, H.

AU - Atzeni, F.

AU - Primdahl, J.

AU - Södergren, A.

AU - Jonsson, S. Wallberg

AU - van Rompay, J.

AU - Zabalan, C.

AU - Pedersen, T. R.

AU - Jacobsson, L.

AU - de Vlam, K.

AU - Gonzalez-Gay, M. A.

AU - Semb, A. G.

AU - Kitas, G. D.

AU - Smulders, Y. M.

AU - Szekanecz, Z.

AU - Sattar, N.

AU - Symmons, D. P M

AU - Nurmohamed, M. T.

PY - 2016/10/3

Y1 - 2016/10/3

N2 - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal antiinflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.

AB - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal antiinflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.

UR - http://www.scopus.com/inward/record.url?scp=84991585385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991585385&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2016-209775

DO - 10.1136/annrheumdis-2016-209775

M3 - Article

AN - SCOPUS:84991585385

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

ER -